Eduard Veseliny

Dr. Eduard Veseliny


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2014 in European Journal of Internal Medicine
Verified
Journal Article
Closed access
Peter JarcuskaPeter Jarcuska
Peter Jarcuska
MJMartin Janicko
Martin Janicko
Peter KruzliakPeter Kruzliak
Peter Kruzliak
MNMiroslav Novák
Miroslav Novák
EVEduard Veseliny
Eduard Veseliny
EKEva Kolesárová
Eva Kolesárová

1 January 2021 in Canadian Journal of Gastroenterology and Hepatology
Verified
Journal Article
Open access
PDF file
SDSylvia Dražilová
Sylvia Dražilová
EVEduard Veseliny
Eduard Veseliny
PLPatricia Denisa Lenartova
Patricia Denisa Lenartova
DSDagmar Simkova
Dagmar Simkova
JGJakub Gazda
Jakub Gazda
Peter JarcuskaPeter Jarcuska
Peter Jarcuska
IgG4‐related sclerosing cholangitis, a biliary manifestation of an IgG4‐related disease, belongs to the spectrum of sclerosing cholangiopathies which result in biliary stenosis. It presents with signs of cholestasis and during differential diagnosis it should be distinguished from cholangiocarcinoma or from other forms of sclerosing cholangitis (primary and secondary sclerosing cholangitis). Despite increasing information and recently established diagnostic criteria, IgG4‐related sclerosing cholangitis remains underdiagnosed in routine clinical practice. The diagnosis is based on a combination of the clinical picture, laboratory parameters, histological findings, and a cholangiogram. Increased serum IgG4 levels are nonspecific but are indeed a part of the diagnostic criteria proposed by the Japan Biliary Association and the HISORt criteria for IgG4‐SC. High serum IgG4 retains clinical utility depending on the magnitude of elevation. Approximately 90% of patients have concomitant autoimmune pancreatitis, while 10% present with isolated biliary involvement only. About 26% of patients have other organ involvement, such as IgG4‐related dacryoadenitis/sialadenitis, IgG4‐related retroperitoneal fibrosis, or IgG4‐related renal lesions. A full‐blown histological finding characterized by IgG4‐enriched lymphoplasmacytic infiltrates, obliterative phlebitis, and storiform fibrosis is difficult to capture in practice because of its subepithelial localization. However, the histological yield is increased by immunohistochemistry, with evidence of IgG4‐positive plasma cells. Based on a cholangiogram, IgG‐4 related sclerosing cholangitis is classified into four subtypes according to the localization of stenoses. The first‐line treatment is corticosteroids. The aim of the initial treatment is to induce clinical and laboratory remission and cholangiogram normalization. Even though 30% of patients have a recurrent course, in the literature data, there is no consensus on chronic immunosuppressive maintenance therapy. The disease has a good prognosis when diagnosed early.

MHMonika Halánová
Monika Halánová
EVEduard Veseliny
Eduard Veseliny
ZKZuzana Kalinová
Zuzana Kalinová
Peter JarcuskaPeter Jarcuska
Peter Jarcuska
MJMartin Janicko
Martin Janicko
Andrea Madarasova GeckovaAndrea Madarasova Geckova
Andrea Madarasova Geckova
Hepatitis E infection is one of the most frequent causes of acute hepatitis in the world. Currently five human genotypes with different geographical distributions and distinct epidemiologic patterns are identified. In Slovakia, only rare cases of hepatitis E have been reported in past years. Because the most important risk factors associated with HEV infection include consumption of contaminated pork meat and poor hygienic standards, the aim of the study was to evaluate the prevalence of anti-HEV total antibodies and the main risk factors for HEV in the population living in separated and segregated Roma settlements (n = 195), which represent places with increased risk of infection in Slovakia and to compare it with the prevalence in the general population (n = 69). Of 264 respondents included in the study, 47 (17.8%) showed positivity for anti-HEV antibodies, 42 of whom were Roma (21.5%, n = 195) and 5 (7.2%, n = 69) non-Roma. The population living in Roma settlements lives in poorer conditions and are at higher risk of HEV in comparison to the general population. However, differences in living conditions within the settlements do not contributed to lower risk of HEV antibody prevalence between Roma living in settlements.

DADaniela Antolová
Daniela Antolová
MJMartin Janicko
Martin Janicko
MHMonika Halánová
Monika Halánová
Peter JarcuskaPeter Jarcuska
Peter Jarcuska
Andrea Madarasova GeckovaAndrea Madarasova Geckova
Andrea Madarasova Geckova
HTHepaMeta Team
HepaMeta Team
The lifestyle, health and social status of the Roma are generally below the standards characteristic for the non-Roma population. This study aimed to find out the seropositivity to Toxoplasma gondii (T. gondii) in the population of Roma living in segregated settlements and to compare it with the prevalence of antibodies in the non-Roma population from the catchment area of eastern Slovakia. The seroprevalence of antibodies to T. gondii was significantly higher in the Roma group (45.0%) than in non-Roma inhabitants (24.1%). A statistically significant difference was also recorded between the two non-Roma groups in the study, 30.4% of those from the catchment area and 19.7% from the non-catchment area were seropositive. Univariate logistic regression confirmed poverty and higher age to be significant risk factors influencing the seropositivity to T. gondii. Of the clinical symptoms analyzed in the study, only muscle and back pain were associated with seropositivity to T. gondii. The close contact of Roma with an environment contaminated by different infectious agents and the insufficient hygiene, lower level of education, poverty, lack of water and household equipment and high number of domestic animals increase the risk of infectious diseases in the Roma settlements and subsequently the spread of communicable diseases at the national or even international level.

28 September 2022 in Surgical Endoscopy
Verified
Journal Article
Closed access
PDF file
DSDagmar Simkova
Dagmar Simkova
JMJan Mares
Jan Mares
ZVZuzana Vackova
Zuzana Vackova
THTomas Hucl
Tomas Hucl
PSPetr Stirand
Petr Stirand
JMJan Martinek
Jan Martinek

25 January 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
LGLaura Gombošová
Laura Gombošová
JDJana Deptová
Jana Deptová
IJIvana Jochmanová
Ivana Jochmanová
TSTatiana Svoreňová
Tatiana Svoreňová
EVEduard Veseliny
Eduard Veseliny
MŠMatej Škorvánek
Matej Škorvánek
Background: To date, no studies comparing complication rates between patients with nutritional percutaneous endoscopic gastrostomy (N-PEG) and Parkinson’s disease (PD) patients with percutaneous endoscopic gastro-jejunostomy (JET-PEG) for treatment administration have been published. Our study aimed to compare complication rates and the number of re-endoscopies between N-PEG and JET-PEG patients. Methods: Individuals requiring N-PEG or JET-PEG insertion between 2014 and 2021 were included in this single-center retrospective observational study. Complications were divided into time-related medical and technical complications. Reasons for post-insertion re-endoscopies and their number were also analyzed. Results: Eighty-seven subjects, 47 (54.02%) in JET-PEG group and 40 (45.98%) in the N-PEG group, were included. Early and technical complications were more frequent in JET-PEG vs. N-PEG subjects (70% vs. 10% [p < 0.001], and 54.5% vs. 5.1% [p < 0.001], respectively). The presence of psychiatric disease was associated with a higher number of early complications (p < 0.002). All three types of complications were significantly more frequent in subjects where a healthcare professional did not handle PEG (p < 0.001). Subjects with JET-PEG required a higher number of re-endoscopies compared to the N-PEG group (57.1% vs. 35%, p = 0.05). Conclusions: Complications are significantly more common in individuals with JET-PEG than those with N-PEG, which can be attributed to higher mobility in PD patients.